Program Description & Educational Objectives

In this activity, experts in colorectal cancer discuss the modern management of advanced disease.

Upon completion of this activity, participants will be able to:

• Summarize recent safety and efficacy data on established and emerging modern cytotoxic and targeted strategies in advanced colorectal cancer (CRC)
• Recommend and accurately interpret the results of molecular testing for a patient with metastatic CRC
• Cite and/or develop effective treatment strategies comprised of cytotoxic and targeted components across newly diagnosed and pretreated advanced CRC settings
• Effectively anticipate or manage treatment-related adverse events in the advanced CRC setting in order to maintain patients on therapy
• Describe the clinical potential of novel biomarkers currently under investigation in metastatic CRC

Target Audience

This activity has been designed to meet the educational needs of oncologists, pathologists, hematologist/oncologists, advanced practice oncology nurses, pharmacists, and other clinicians involved in the management of advanced colorectal cancer.

Requirements for Successful Completion

In order to receive credit, participants must view the activity and complete the post-test and evaluation form. There are no pre-requisites and there is no fee to participate in this activity or to receive CME/CNE/CPE credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

Media: Internet
Release and Expiration Dates: February 02, 2012 - February 01, 2013
Time to Complete: 60 minutes

Faculty & Disclosure / Conflict of Interest Policy

All faculty AND staff involved in the planning or presentation of continuing education activities sponsored/provided by Purdue University College of Pharmacy are required to disclose to the audience any real or apparent commercial financial affiliations related to the content of the presentation or enduring material. Full disclosure of all commercial relationships must be made in writing to the audience prior to the activity.

Course Director and Moderator

Axel Grothey, MD
Professor of Oncology
Division of Medical Oncology
Mayo Clinic
Rochester, Minnesota

Axel Grothey, MD, has a financial interest/relationship or affiliation in the form of:
Grant/Research Support from Bayer AG; Daiichi Sankyo, Inc.; Eli Lilly and Company; and Genentech, Inc.

Interviewees

John L. Marshall, MD
Professor of Hematology/Oncology
Department of Medicine
Georgetown University Hospital
Washington, District of Columbia

John L. Marshall, MD, has a financial interest/relationship or affiliation in the form of:
Consultant for Amgen Inc. and Genentech, Inc.
Grant/Research Support from Amgen Inc. and Genentech, Inc.
Speakers Bureau participant with Amgen Inc. and Genentech, Inc.
Advisory Board for Amgen Inc. and Genentech, Inc.

Heinz-Josef Lenz, MD
Professor of Medicine and Preventive Medicine
Kathryn Balakrishnan Chair for Cancer Research
Associate Director, Clinical Research
Co-Chair GI Oncology
Co-Director USC Center for Molecular Pathways and Drug Discovery
USC/Norris Comprehensive Cancer Center
Los Angeles, California

Heinz-Josef Lenz, MD, has a financial interest/relationship or affiliation in the form of:
Consultant for Bristol-Myers Squibb; Genentech, Inc.; Merck KG; Novartis Pharmaceuticals Corporation; and Response Genetics, Inc.
Grant/Research Support from Bristol-Myers Squibb; Cancer Therapy Evaluation Program; Eli Lilly and Company; F. Hoffmann-La Roche Ltd; Genentech, Inc.; GlaxoSmithKline; Merck & Co., Inc.; National Cancer Institute; National Institutes of Health; Novartis Pharmaceuticals Corporation; Pfizer Inc; sanofi-aventis; and SWOG.
Honoraria from Bristol-Myers Squibb; Genentech, Inc.; Merck KG; and Response Genetics, Inc.
Other Financial or Material Support from Response Genetics, Inc. in the form of stock options.

Content Director

Carmine DeLuca
PVI, PeerView Institute for Medical Education

Carmine DeLuca currently has no financial interests/relationships or affiliations in relation to this activity.

All additional planning committee members, PVI, PeerView Institute for Medical Education, Inc. staff, and Purdue University College of Pharmacy staff have no relationships to disclose.

Sponsorship, Credit & Support

Physicians

This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of Purdue University College of Pharmacy and PVI, PeerView Institute for Medical Education. Purdue University College of Pharmacy, an equal access/equal opportunity institution, is accredited by the ACCME to provide continuing medical education for physicians.

The Purdue University College of Pharmacy designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses

Purdue University Continuing Nursing Education, West Lafayette, IN (ISNA No. CNEP 11-03, Exp. 06/1/2014) is an approved provider of continuing nursing education by the Indiana State Nurses Association, an accredited approver by the American Nurses Credentialing Center’s Commission on Accreditation.

This activity has been approved for 1.0 contact hour(s).

Pharmacists

Purdue University College of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This is a knowledge-based, continuing education activity of Purdue University, an equal access/equal opportunity institution. Universal Activity Number (UAN): 0018-9999-12-003-H01-P, 1.0 contact hours (0.1 CEUs).

Release Date: February 02, 2012 Expiration Date: February 01, 2013

This CME/CNE/CPE activity is jointly sponsored by Purdue University College of Pharmacy and PVI, PeerView Institute for Medical Education.

This activity is supported by educational grants from Bristol-Myers Squibb, Genentech, Inc., and Lilly USA, LLC.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use.

No endorsement of unapproved products or uses is made or implied by coverage of these products or uses in our reports. No responsibility is taken for errors or omissions in reports.

Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings.

The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PeerView Press or any of its supporters.